Vimarsana
Biggest News Aggregation in the World

Page 3 - Between Aug News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Between Aug. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Between Aug Today - Breaking & Trending Today

Piroxicam may augment the clinical efficacy of levonorgestrel in emergency contraception - Vimarsana News

Piroxicam may augment the clinical efficacy of levonorgestrel in emergency contraception

1. Levonorgestrel plus piroxicam resulted in significantly fewer pregnancies compared to placebo. 2. There were no changes with respect to menstrual cycle advancement or delay in each group. Evidence Rating Level: 1 (Excellent) Study Rundown: Levonorgestrel is a commonly used emergency contraceptive; however, its therapeutic benefits require it to be used prior to ovulation. Whether

Use of dual antibiotic loaded cement does not reduce surgical site infection rates in patients undergoing hemiarthroplasty - Vimarsana News

Use of dual antibiotic loaded cement does not reduce surgical site infection rates in patients undergoing hemiarthroplasty

1. Deep surgical site infection at 90 days was 1.7% in the single-antibiotic group versus 1.2% in the dual-antibiotic loaded cement group, with no significant differences between groups. 2. Quality of life, mobility, and mortality at 120 days were comparable between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Hip fracture is a common

#VisualAbstract: Low-molecular-weight heparin does not improve live birth rates in women with recurrent pregnancy loss and thrombophilia - Vimarsana News

#VisualAbstract: Low-molecular-weight heparin does not improve live birth rates in women with recurrent pregnancy loss and thrombophilia

1. Live birth rate between the low-molecular-weight heparin and standard care group was comparable. 2. The most common inherited thrombophilia were heterozygous Factor V Leiden followed by heterozygous Prothrombin G20210A mutations. Evidence Rating Level: 1 (Excellent) Study Rundown: Thrombophilia is a leading cause of recurrent miscarriage around the world. Although anticoagulant therapy may reduce the number of

Fruquintinib significantly improves survival in patients with refractory metastatic colorectal cancer - Vimarsana News

Fruquintinib significantly improves survival in patients with refractory metastatic colorectal cancer

1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse events were mild-to-moderate and were slightly more common among patients receiving fruquintinib. Evidence Rating Level: 1 (Excellent) Study Rundown: Colorectal cancer is the third-most prevalent cancer in the world and the second leading cause of death worldwide. Patients

Low-molecular-weight heparin does not improve live birth rates in women with recurrent pregnancy loss and thrombophilia - Vimarsana News

Low-molecular-weight heparin does not improve live birth rates in women with recurrent pregnancy loss and thrombophilia

1. Live birth rate between the low-molecular-weight heparin and standard care group was comparable. 2. The most common inherited thrombophilia were heterozygous Factor V Leiden followed by heterozygous Prothrombin G20210A mutations. Evidence Rating Level: 1 (Excellent) Study Rundown: Thrombophilia is a leading cause of recurrent miscarriage around the world. Although anticoagulant therapy may reduce the